


Technology Advisory Committee A Interests Register Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Publication Date: 21/07/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Dominic Pivonka	TA Committee A Member	Direct - financial	Mr Pivonka's employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis, upadacitinib.	NA	09/02/2021	NA	It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Rita Faria	TA Committee A Member	Indirect interests	Dr Faria works at the same university as the Evidence Review Group for this appraisal. She had no knowledge or input into this appraisal prior to it being discussed at committee.	NA	02/02/2021	NA	It was agreed that this declaration would not prevent Dr Faria from participating in this section of the meeting.
Professor Abdallah Al- Mohammed	TA Committee A Member	Direct - financial	Attended advisory board with Novartis in October 2019, related to publication of the PARAGON study. This study was in an unrelated disease area. Also received honoraria in July 2020, to give a presentation to Novartis staff on heart failure.	NA	06/05/2021	NA	It was agreed that these declarations would not prevent Professor Al-Mohammad from participating in this section of the meeting.



Dr Raj Sengupta	Clinical expert	Direct - financial	Received grants, honoraria for advisory boards, speaker event fees and support for conference attendance from Novartis, Abbvie, Biogen, Celgene and UCB.	NA	29/10/2019	NA	It was agreed that these declarations would not prevent Dr Sengupta from providing expert advice to the committee.
Dr Raj Sengupta	Clinical expert	Direct - financial	Received grants, honoraria for advisory boards, speaker event fees and support for conference attendance from Lilly, Roche and MSD	NA	16/02/2021	NA	It was agreed that these declarations would not prevent Dr Sengupta from providing expert advice to the committee.
Dr Louise Warburton	Clinical expert	Direct - financial	Partook in a webinar talk for MIMS Live on Osteoporosis which was pharma sponsored in November 2020.	NA	18/02/2021	NA	It was agreed that this declaration would not prevent Dr Warburton from providing expert advice to the committee.
Dr Louise Warburton	Clinical expert	Direct non- financial interests	Dr Warburton is a NICE fellow and is on the Executive Committee of the Primary Care Rheumatology and MSK Medicine Society, supported by pharma.	NA	18/02/2021	NA	It was agreed that these declarations would not prevent Dr Warburton from providing expert advice to the committee.